Published in J Immunol on March 15, 2008
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm (2012) 1.16
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta (2008) 1.06
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta (2009) 1.05
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets (2008) 0.89
C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol (2014) 0.88
Atherosclerosis-related functions of C-reactive protein. Cardiovasc Hematol Disord Drug Targets (2010) 0.87
Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm (2014) 0.86
Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J Biol Chem (2011) 0.86
Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis. J Biol Chem (1992) 0.85
The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH. Clin Chim Acta (2009) 0.81
The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine. J Inflamm (Lond) (2012) 0.80
Therapeutic potential of phosphoethanolamine-bound C-reactive protein in atherosclerosis. Future Lipidol (2008) 0.77
Functional transformation of C-reactive protein by hydrogen peroxide. J Biol Chem (2017) 0.75
Action mechanism and cardiovascular effect of anthocyanins: a systematic review of animal and human studies. J Transl Med (2016) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol (1985) 8.03
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation (2006) 3.35
Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med (1971) 3.32
C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation (2001) 2.66
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 2.43
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A (2002) 2.20
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation (2002) 1.94
CRP after 2004. Mol Immunol (2004) 1.91
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest (1963) 1.88
C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol (2000) 1.88
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol (1999) 1.86
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol (2005) 1.70
Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol (2005) 1.66
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62
Comparative studies on the binding properties of human and rabbit C-reactive proteins. J Immunol (1980) 1.59
C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol (2005) 1.37
Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci U S A (2007) 1.37
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med (1987) 1.27
C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med (2004) 1.26
7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res (1997) 1.26
Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation (2004) 1.26
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 1.24
Macrophage foam cells and atherosclerosis. Front Biosci (2001) 1.24
Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology (2006) 1.16
A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol (2002) 1.14
Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J (2002) 1.10
Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol (2006) 1.08
Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem (2004) 1.00
Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol (2005) 0.99
Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry (1992) 0.99
C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther (2002) 0.98
C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol (2005) 0.96
C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun (2005) 0.96
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J Immunol (2007) 0.95
Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J (2002) 0.94
Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol (2005) 0.94
C-reactive protein inhibits in vitro oxidation of low-density lipoprotein. FEBS Lett (2006) 0.91
Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Hokkaido Igaku Zasshi (1990) 0.90
C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol (2004) 0.90
Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice. Drug Metab Dispos (1998) 0.89
Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol (1998) 0.86
Rat C-reactive protein causes a charge modification of LDL and stimulates its degradation by macrophages. Arterioscler Thromb (1994) 0.80
Sodium azide in commercially available C-reactive protein preparations does not influence matrix metalloproteinase-2 synthesis and release in cultured human aortic vascular smooth muscle cells. Clin Chem (2006) 0.79
Immunochemical recognition of the binding of C-reactive protein to solid-phase phosphorylethanolamine. Rev Esp Fisiol (1988) 0.79
A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract (2003) 2.32
Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol (2011) 1.83
Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem (2007) 1.69
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol (2011) 1.26
PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology (2010) 1.21
Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS One (2011) 1.19
Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem (2010) 1.14
Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. J Immunol (2005) 1.13
Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett (2004) 1.11
PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma. Immunol Cell Biol (2010) 1.07
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta (2008) 1.06
Lomotil dependence: a note of caution. Natl Med J India (2006) 1.06
Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry (2006) 1.05
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta (2009) 1.05
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol (2006) 1.01
Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem (2004) 1.00
Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection. Arch Immunol Ther Exp (Warsz) (2013) 1.00
HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3/Gal-9 pathway. Eur J Immunol (2012) 0.97
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
Sepsis and meningitis due to Capnocytophaga cynodegmi after splenectomy. Clin Infect Dis (2005) 0.95
Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection. J Virol (2013) 0.94
HSPA12B is predominantly expressed in endothelial cells and required for angiogenesis. Arterioscler Thromb Vasc Biol (2006) 0.94
Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol (2005) 0.94
Differential regulation of T and B lymphocytes by PD-1 and SOCS-1 signaling in hepatitis C virus-associated non-Hodgkin's lymphoma. Immunol Invest (2011) 0.93
Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem (2002) 0.92
Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection. Viral Immunol (2010) 0.91
Down-regulation of expression and function of nucleoside diphosphate kinase in insulin-secreting beta-cells under in vitro conditions of glucolipotoxicity. Mol Cell Biochem (2009) 0.91
Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning. Bull World Health Organ (2013) 0.89
The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets (2008) 0.89
Hepatitis C: the complications of immune dysfunction. Expert Rev Clin Immunol (2007) 0.89
The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct. Mol Immunol (2003) 0.88
A 45-year-old woman with fever and splenic infarcts. Clin Infect Dis (2003) 0.88
Bronchiolitis obliterans organizing pneumonia as a manifestation of AIDS: case report and literature review. J Infect (2004) 0.88
Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection. Vaccine (2013) 0.87
Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J Biol Chem (2011) 0.86
Scale-up of opioid substitution therapy in India: opportunities and challenges. Int J Drug Policy (2012) 0.85
Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6. Hepatology (2015) 0.85
Prosthetic joint infection by Mycobacterium tuberculosis: an unusual case report with literature review. South Med J (2007) 0.85
KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection. J Immunol (2013) 0.85
Oct-1 acts as a transcriptional repressor on the C-reactive protein promoter. Mol Immunol (2012) 0.84
Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Immunology (2014) 0.83
Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. J Innate Immun (2014) 0.83
Clinical manifestations and diagnosis of influenza. South Med J (2003) 0.83
Cis association of galectin-9 with Tim-3 differentially regulates IL-12/IL-23 expressions in monocytes via TLR signaling. PLoS One (2013) 0.82
Induction of p38- and gC1qR-dependent IL-8 expression in pulmonary fibroblasts by soluble hepatitis C core protein. Respir Res (2005) 0.81
The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH. Clin Chim Acta (2009) 0.81
An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis (2005) 0.81
Role of pulmonary artery reactivity and nitric oxide in injury and inflammation following lung contusion. Shock (2013) 0.81
The phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of mice against pneumococcal infection. J Biol Chem (2012) 0.81
Complications of influenza. South Med J (2003) 0.80
CRP can play both pro-inflammatory and anti-inflammatory roles. Mol Immunol (2006) 0.80
Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection. South Med J (2006) 0.80
KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection. J Virol (2013) 0.80
Loss of von Hippel-Lindau protein (VHL) increases systemic cholesterol levels through targeting hypoxia-inducible factor 2α and regulation of bile acid homeostasis. Mol Cell Biol (2014) 0.79
Strongyloides hyperinfection syndrome complicating (ectopic) Cushing syndrome. South Med J (2008) 0.79
Type of opioids injected: does it matter? A multicentric cross-sectional study of people who inject drugs. Drug Alcohol Rev (2014) 0.78
A novel RBP-J kappa-dependent switch from C/EBP beta to C/EBP zeta at the C/EBP binding site on the C-reactive protein promoter. J Immunol (2007) 0.78
Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. Immunology (2014) 0.77
Computational analysis of C-reactive protein for assessment of molecular dynamics and interaction properties. Cell Biochem Biophys (2013) 0.76
Diagnostic dilemma: A case of self-injurious behavior. Indian J Psychiatry (2011) 0.75
A 32-year-old man with skin lesions. Clin Infect Dis (2004) 0.75
Molecular Characterization of Hypoxic Alveolar Epithelial Cells After Lung Contusion Indicates an Important Role for HIF-1α. Ann Surg (2016) 0.75
Lactic acidosis during nucleoside antiretroviral HIV therapy. South Med J (2004) 0.75
India's National Narcotic Drugs and Psychotropic Substances policy, 2012: a 20th century document in the 21st century. Int J Drug Policy (2013) 0.75
Combining cytomorphology and serology for the diagnosis of cat scratch disease. Diagn Cytopathol (2011) 0.75
Case report and literature review: HHV-6-associated meningoencephalitis in an immunocompetent adult. Herpes (2008) 0.75
Lingering lesions. Am J Med (2008) 0.75
Peritoneal blastomycosis: a hidden mystery unfolds itself. Conn Med (2014) 0.75
A woman with nodular skin lesions. Clin Infect Dis (2005) 0.75
Severe acute respiratory syndrome: an overview. South Med J (2003) 0.75